Glaxo Group Limited

Domantis Limited

Lipotek Pty Ltd

Rudolf Maria De Wildt

Steve Holmes

Christopher Richard Parish

Jonathan Henry Ellis

Paul Andrew Hamblin

Stephanie Jane Clegg

Claire Ashman

Caroline Dimech

Michael Steward

Ines Atmosukarto

Jason David Price

Adriaan Allart Stoop

Joseph Altin

Farhana Hussain

Michael Neil Burden

Martin Anibal Orecchia

Radha Shah

Thil Batuwangala

The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. The disclosure also provides a polypeptide, ligand or pharmaceutical composition for treating a disease associated with TGFbeta signaling and a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis, liver fibrosis, including cirrhosis and chronic hepatitis, rheumatoid arthritis, ocular disorders, or fibrosis of the skin, including keloid of skin, and kidney such as nephritis, kidney fibrosis and nephrosclerosis, and a vascular condition, such as restenosis.

Ligands that bind TGF-&#x3b2; receptor RII

The present disclosure relates to a composition for targeting dendritic cells. In particular, the present disclosure relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The disclosure further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.

Composition for targeting dendritic cells

Growing community of inventors

Stevenage, United Kingdom

Rudolf Maria De Wildt